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Abstract HIV-1 external envelope glycoprotein gp120 inhibits
adenosine deaminase (ADA) binding to its cell surface receptor in
lymphocytes, CD26, by a mechanism that does not require the
gp120^CD4 interaction. To further characterize this mechanism,
we studied ADA binding to murine clones stably expressing
human CD26 and/or human CD4, and transiently expressing
human CXCR4. In this heterologous model, we show that both
recombinant gp120 and viral particles from the X4 HIV-1 isolate
IIIB inhibited the binding of ADA to wild-type or catalytically
inactive forms of CD26. In cells lacking human CXCR4
expression, this gp120-mediated inhibition of ADA binding to
human CD26 was completely dependent on the expression of
human CD4. In contrast, when cells were transfected with human
CXCR4 the inhibitory effect of gp120 was significantly enhanced
and was not blocked by anti-CD4 antibodies. These data suggest
that the interaction of gp120 with CD4 or CXCR4 is required for
efficient inhibition of ADA binding to CD26, although in the
presence of CXCR4 the interaction of gp120 with CD4 may be
dispensable. ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
CD26 is a 105^110 kDa well-characterized multifunctional
cell surface protein [1], known to show an intrinsic dipeptidyl
peptidase (DPP IV) activity [2] and to be the receptor of the
43 kDa ecto-enzyme adenosine deaminase (ADA) [3,4]. In
peripheral blood T lymphocytes, CD26 expression is highly
regulated and enhanced upon T-cell activation [5]. CD26 is
able to deliver intracellular signals, probably by means of its
physical association with the membrane-linked tyrosine phos-
phatase CD45 [6]. This signaling capacity allows anti-CD26
mAbs or the natural occurring CD26 ligand, ADA, to have a
costimulatory e¡ect in TCR-mediated T-cell activation [7,8].
The expression of CD26 has been controversially correlated to
HIV infection [9^12]. However, the ability of CD26 to cleave
and modify the activity of HIV-1-inhibitory chemokines, such
as the CXCR4 ligand SDF-1 [14] has highlighted the role of
DPP IV activity of CD26 in HIV infection [13]. Moreover, we
have reported that HIV-1 envelope protein gp120 inhibits the
interaction between ADA and CD26 on the surface of human
cells [15]. This inhibitory e¡ect is independent of HIV infec-
tion and does not require the expression of the HIV receptor,
the CD4 molecule [15].
The HIV-induced inhibition of ADA binding to CD26 sug-
gests the existence of a functional interaction between cell
surface-expressed CD26 and HIV-1 gp120. However, the
mechanisms of this interaction, which are mediated by the
C3 region of gp120 [15], remain unclear. The aim of this paper
was to further characterize the interaction of gp120 with
CD26. For this purpose, the gp120-induced inhibition of
ADA binding to human CD26 was studied in murine cells
expressing human CD26, CD4 and CXCR4. The role of the
peptidase activity of CD26 was also investigated by using cells
expressing the S630A mutant form of human CD26, which
lacks DPP IV activity. Our results show that both, soluble
gp120 and HIV-1 particles are able to inhibit the binding of
ADA to human CD26 irrespective of DPP IV activity of
CD26. Inhibition was completely dependent on CD4 expres-
sion in CXCR43 cells. The transfection of CXCR4 enhances
the inhibitor e¡ect of gp120 and makes the gp120^CD4 inter-
action dispensable, thus suggesting that gp120-mediated ADA
binding inhibition is also CXCR4-dependent. The reduced
ability of ADA to bind to CD26 in the presence of gp120
may a¡ect T-cell function during HIV infection and may ex-
plain the correlation found between increased levels of serum
ADA and the evolution of AIDS in HIV-1-infected individu-
als [16,17].
2. Materials and methods
2.1. Cells and antibodies
Murine clones expressing human CD26 were obtained as described
[18]. Clones were selected by their expression of human CD26. Clones
having lost human CD4 expression were used as control clones in
di¡erent experiments.
Monoclonal antibodies TA5.9-CC1^4C8 directed against the ADA
binding site in CD26 [4], and CB-T4 directed against the gp120 bind-
ing site in CD4 were kindly provided by Dr. E. Bossman, Euroge-
netics, Tessenderlo and have been previously characterized [15,19].
2.2. Analysis of expression of cell surface proteins
Human CD26, human CD4 and human CXCR4 expression in dif-
ferent murine clones were determined by FACS analysis using the
anti-human CD26 PE-labeled mAb Tal (Coulter), the anti-human
CD4 FITC-labeled mAb OKT4 (Ortho), and the PE-labeled anti-
CXCR4 mAb 12G5 (Pharmingen), respectively. Incubations were per-
formed in FACS bu¡er (1% bovine serum albumin and 0.01% sodium
azide in PBS) at 4‡C for 30 min. After incubations, cells were washed
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twice, ¢xed in FACS bu¡er containing 1% formaldehyde and analyzed
in a FACS scan £ow cytometer (Becton Dickinson, Mountain View,
CA, USA) using the Lysis II software. Cell surface expression of
CD26 was also monitored by determining the cleavage of GP-pNA
(Glycylprolyl-p-nitroanilide, Sigma) as described previously, in order
to con¢rm the phenotype of both forms of CD26 [18].
2.3. HIV-1 gp120, peptides and viral preparations
Recombinant HIV-1 envelope glycoprotein gp120 from the X4 iso-
late IIIB (construct deposited by Dr. I. Jones) and peptides covering
the entire sequence of this protein [15] were kindly provided by the
Medical Research Council AIDS Directed Program Reagent Project
(Potters Bar, UK).
For the preparation of an HIV-1 stock, CEM cells were infected
with a high dose of HIV-1 Lai (1 h, 37‡C), washed and cultured for 3^
4 days. Culture supernatant (500Ug, 10 min) was then recovered and
stored at 3135‡C. Prior to use, thawed viral preparations were ¢ltered
through 0.22 Wm pore size ¢lters and centrifuged 50 000Ug for 1 h at
4‡C to eliminate free ADA that could interfere in the binding assays.
Pellets were resuspended in fresh RPMI medium, usually in a third of
the original volume.
2.4. Labeling of bovine ADA
Bovine ADA (Sigma Type VIII) was either iodinated by using the
Bolton-Hunter reagent (DuPont, NEN) as described [18], or labeled
with FITC. Brie£y, ADA was dialyzed against labeling bu¡er (50 mM
H3BO3, 200 mM NaCl, pH 9.2) at 4‡C, and treated with £uorescein
isothiocyanate (FITC, 5 mg/ml in DMSO) in a ratio of 0.1 mg of
FITC per mg of protein. After 2 h at room temperature, unbound
£uorochrome was separated by gel ¢ltration using a Sephadex G-25
column.
2.5. FITC-labeled ADA binding
Cells (4U106) were washed twice with PBS and were incubated
successively in the absence or the presence of anti-CD4 mAb CB-T4
(1 Wg/ml, 15 min at 37‡C), gp120 (100 mM, 15 min at 37‡C) and
FITC-labeled ADA (100 mM, 30 min at 37‡C). The control for bind-
ing speci¢city was performed by preincubating cells with unlabeled
ADA (4 WM, 15 min at 37‡C) before addition of labeled ADA (100
nM). After incubation, cells were washed twice in ice-cold PBS and
¢xed in 2% paraformaldehyde, 60 mM sucrose in PBS, for 15 min at
room temperature. Then, cells were washed twice with 20 mM glycine
in PBS (bu¡er A) and incubated with the same bu¡er containing 1%
BSA and 0.05% NaN3 before £ow cytometry analysis in a EPICS
Pro¢le £ow cytometer (Coulter; Hialeah, FL, USA). The parameters
used to select cell populations for analysis were forward and side light
scatter.
2.6. 125I-labeled ADA binding
Cells were washed twice and resuspended at 1U107 cells/ml. Ali-
quots of 0.5U106 cells were preincubated (15 min, 37‡C) in the pres-
ence or the absence of binding inhibitors (unlabeled ADA, mAb
TA5.9, mAb CB-T4, gp120) and then incubated with 15 nM 125I-
labeled ADA in a ¢nal volume of 100 Wl. After incubation (1 h,
37‡C), cells were washed twice in cold PBS and lysed in 100 Wl E
bu¡er (20 mM Tris^HCl, 150 mM NaCl, 5 mM MgCl2, 0.2 mM
PMSF, 100 U/ml aprotinin, 0.5% Triton X-100 and 7 mM 2-mercap-
toethanol, pH 7.6). Lysates were centrifuged (10 000Ug for 5 min at
4‡C) to eliminate nuclei, and supernatants were diluted with one vol-
ume of SDS^PAGE sample bu¡er [20]. Following SDS^PAGE, gels
were ¢xed, dried and radioactivity associated with the 43 kDa 125I-
labeled ADA bands were quanti¢ed in a Phosphorimager (Molecular
Dynamics, Sunnyvale, CA, USA). In experiments designed to calcu-
late Kd values, the binding of increasing concentrations of 125I-labeled
ADA (from 1 to 100 nM) was studied. Binding data were ¢tted using
a non-linear regression program [18].
2.7. Transfection
The CXCR4 and CCR5 expression vectors pCDNAI.Fusin and
pCDNAI.CCR5 were obtained from Dr. N. Landau through the
HIH AIDS Research and Reference Reagent Program. W12 cells
(4U106) were transiently transfected with 2 Wg of plasmid using the
Superfect Reagent from Qiagen (Hilden, Germany) as recommended
by the manufacturer. Cells were grown for 40 h, before evaluation of
CXCR4 and CCR5 expression by £ow cytometry using 12G5 and
2D7 antibodies (Pharmingen).
3. Results
3.1. 125I-labeled ADA binding to murine cells
Murine cells are an useful model to study the ADA binding
to human CD26 since 125I-labeled ADA does not compete
with endogenous murine ADA, which is not able to bind to
human CD26 [18]. We selected several murine clones stably
transfected with human CD4 and CD26. Most of the selected
clones expressing human CD26 also expressed human CD4, as
in the case of the clone W12, transfected with wild-type hu-
man CD26, or in the clone M9, transfected with the S630A-
mutated form of human CD26 (Fig. 1). Some clones, which
lost human CD4 expression during selection and further cul-
turing (Fig. 1, Clone M7) were used as CD4 negative control
cells. To evaluate the presence of a functional ADA binding
site on CD26-transfected cells, we studied the a⁄nity of 125I-
labeled ADA binding to these cells and, for comparison, to
CD26-expressing human cell lines. The Kd values found in all
cells assayed were similar (Table 1) irrespective of the level of
CD26 expression. Consistent with the speci¢city of the ADA^
CD26 interaction under these experimental conditions, bind-
ing was inhibited to a similar extent in the presence of the
mAb TA5.9, directed against the ADA binding site in human
CD26, or in the presence of an excess of unlabeled ADA (Fig.
Fig. 1. Cell surface expression of human CD4 and human CD26 in
di¡erent murine clones used. The expression of human CD4 and
human CD26 was assayed by FACS analysis in the wild-type
CD26-expressing clone W12 and the S630A CD26-expressing clones,
M9 and M7. Antibodies used were: PE-labeled mAb Tal speci¢c
for human CD26, FITC-labeled OKT4 speci¢c for human CD4,
and control labeled antibodies (peaks C-PE and C-FITC).
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2). Moreover no speci¢c binding was found in murine cells
lacking human CD26 expression (Table 1). These results con-
¢rm that in this experimental model the interaction ADA^
CD26 is highly speci¢c and is independent of the peptidase
activity of CD26.
3.2. gp120-induced inhibition of 125I-labeled ADA binding to
human CD26 in murine cells expressing human CD4
We studied the e¡ect of soluble gp120 on the binding of
125I-labeled ADA to the wild-type CD26-expressing clone
W12 and to the clone M9, which expresses the S360A mutated
form of human CD26. Preincubation of these cells in the
presence of 100 nM of gp120 resulted in a consistent and
signi¢cant inhibition (40 and 61% in W12 and M9 cells, re-
spectively) of the binding of ADA to human CD26 (Fig. 2).
The e¡ect was dose-dependent (data not shown), and the de-
gree of inhibition was slightly lower but comparable to that
observed in several human cell lines [15]. To map the region of
gp120 implicated in the inhibition of ADA binding to CD26
in the heterologous system, a collection of overlapping pep-
tides that cover the entire sequence of gp120 IIIB was used
(for sequences see Valenzuela et al., 1997) [15]. In the two
clones tested (W12 and M9), only peptides corresponding to
the third constant domain of gp120 (C3 region) were able to
signi¢cantly inhibit the binding of ADA to CD26 (Fig. 2).
These peptides are p31 (HCNISRAKWNNTLKQIDSKL)
and p33 (REQFGNNKTIIFKQSSGGDPE), which corre-
spond to the residues 336^355 and 356^375 of gp120 IIIB,
respectively. These results con¢rm that gp120-induced ADA
binding inhibition is similar in murine and human cells.
3.3. The e¡ect of CD4 expression on gp120-induced ADA
binding inhibition
We next evaluated the requirement of human CD4 in
gp120-induced ADA binding inhibition. Two di¡erent ap-
proaches were used, the ¢rst being the study of the e¡ect of
gp120 on the binding of 125I-labeled ADA to CD26 expressed
in the M7 murine clone, which lacks human CD4 expression.
As shown in Fig. 3A, gp120 did not induce any signi¢cant
decrease in ADA binding to CD26 expressed in the human
CD4 negative clone M7. This clone expresses low levels of
CD26 that could a¡ect the inhibition of ADA binding to
CD26. Therefore, we con¢rmed the requirement for a
gp120^CD4 interaction by assaying the e¡ect of gp120 and
HIV-1 particles in W12 cells preincubated with an anti-human
CD4 mAb (Fig. 3B). The addition of the antibody CB-T4
alone did not modify the binding of 125I-labeled ADA to
CD26, which was inhibited by the addition of 100 nM of
gp120 and a concentrated preparation of viral particles in
the absence of the antibody. However, in the presence of
the anti-CD4 mAb CB-T4, the inhibitory e¡ect of both, solu-
ble gp120 and viral particles, was completely abolished (Fig.
3B). This result contrasts with what happens in human cells,
in which the gp120^CD4 interaction is not required [15].
Therefore, it seems that the inhibition of the binding of 125I-
labeled ADA to CD26 by gp120 is dependent on the interac-
tion of gp120 with human CD4. Moreover, murine clones
Table 1
The binding of 125I-labeled ADA to di¡erent CD26-expressing cells :
e¡ect of HIV-1 IIIB gp120
Cell line ADA binding
a⁄nity Kd (nM)a
Human cells
Jurkat (CD26low/CD4 T-cell line) 15 þ 5
Jurkat (wild-type CD26-transfected, clone #11) 11 þ 3
Jurkat (S630A CD26-transfected, clone D28) 9 þ 4
SKW 6.4(CD26, CD43 B-cell line) 10 þ 1
Murine cells
T6 (human CD263) No binding
W12 (wild-type CD26-transfected) 12 þ 2
M9 (S630A CD26-transfected) 11 þ 4
M7 (S630A CD26-transfected) 10 þ 5
aThe binding of increasing concentrations of 125I-labeled ADA (1^
50 nM) to di¡erent cells was studied. Kd values were calculated by
non-linear regression of binding data as described [18]. Values þ S.D.
given by the program.
Fig. 2. The inhibition of 125I-labeled ADA binding to human CD26
by gp120 is independent of DPP IV activity of CD26 and is medi-
ated by the C3 region of gp120. The e¡ect of either, 100 nM gp120,
or 60 nM of peptides p31 and p33 (corresponding to the C3 region
of gp120, see text for details), on the binding of 15 nM 125I-labeled
ADA to W12 cells, expressing wild-type human CD26 (upper pan-
el), and M9 cells, expressing S630A human CD26 devoid of DPP
IV activity (lower panel), was assayed by SDS^PAGE as described
in Section 2. Unlabeled ADA (4 WM) and the mAb TA5.9 (1 Wg/ml)
were used as controls for speci¢c binding. Results of a typical ex-
periment are presented with a section of the autoradiogram showing
the 43 kDa labeled band corresponding to cell-bound 125I-labeled
ADA. The histogram quanti¢es the associated radioactivity
(mean þ S.E.M. from triplicate samples).
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seem to lack molecules, other than CD4 able to interact with
gp120 to allow a subsequent interaction with CD26.
3.4. The e¡ect of CXCR4 expression on gp120-induced ADA
binding inhibition
The main candidate to mediate the inhibitory e¡ect of
gp120 on ADA binding is the chemokine receptor CXCR4.
We found that murine clones lack murine CXCR4 expression
as assessed by FACS analysis and RT-PCR studies (data not
shown). Therefore, we transiently transfected the W12 murine
clone with human CXCR4 to evaluate the role of this receptor
on the gp120-induced inhibition of ADA binding to CD26. In
these transiently transfected cells the binding of ADA was
studied by FACS analysis using FITC-labeled bovine ADA.
As shown in Fig. 4, transfection of human CXCR4 signi¢-
cantly enhanced the inhibitory e¡ect of gp120. Inhibition was
91% in CXCR4 expressing cells (Fig. 4D) compared to 32% in
control W12 cells (Fig. 4B). The e¡ect was also studied in the
presence of the anti-CD4 mAb CB-T4. In control cells lacking
human CXCR4, the antibody completely reverted the e¡ect of
gp120 (Fig. 4C), whereas in CXCR4-expressing cells a 72%
inhibition of ADA binding was still observed when the inter-
action of gp120 with CD4 was blocked (Fig. 4D). This e¡ect
appeared to be speci¢c for CXCR4 expression since gp120-
induced inhibition of ADA binding to CD26 in CCR5-trans-
fected W12 cells was 39% (Fig. 4E), a value closely similar to
that observed in control cells. Thus, the expression of CXCR4
speci¢cally enhances the inhibitory e¡ect of gp120 on ADA
binding to CD26 and makes the interaction of gp120 with
CD4 dispensable, as it happens in human SKW6.4 cells [15],
which are CXCR4/CD43 (not shown).
4. Discussion
We have previously described the inhibition of ADA bind-
ing to CD26 by gp120 and viral particles [15]. This inhibition
was observed in human CD4 and CD43 cells, thus appear-
ing to be independent of the interaction of HIV-1 gp120 with
CD4 and suggesting a direct interaction between gp120 and
the ADA binding site of CD26. However, the data presented
here in a heterologous model, showing the lack of e¡ect of
gp120 on ADA binding to CD26 in CD43/CD26 murine
cells rule out this possibility, and suggest that gp120 should
interact with other cell surface component(s) prior to its func-
tional interaction with CD26.
Several cell surface components have been shown to inter-
act with external glycoprotein gp120 from R4 HIV-1 isolates,
such as CD4 [21], CXCR4 [22], galactosyl ceramides [23], the
highly charged heparan sulfate proteoglycans [24], and cell-
surface nucleolin [25]. However, it seems clear that gp120
binding induces the formation on the target cell surface of a
complex in which, at least gp120, CD4 and CXCR4 associate
[26,27]. Therefore, it was relevant to investigate the role of
CXCR4 in the gp120-mediated inhibition of ADA binding
to CD26. As a ¢rst approach, we studied the expression of
CXCR4 in the human CD43 B-cell line SKW6.4, which is
sensitive to the gp120-mediated inhibition of the binding of
ADA to CD26 [15]. We observed that this cell line does ex-
press CXCR4. However, the activation of this receptor by
SDF-1 modi¢ed the expression of CD26, and then the binding
of ADA to CD26 (C.H., data in preparation). As an alterna-
tive approach, we evaluated the role of CXCR4 in murine
cells transiently expressing this receptor. Although in murine
CXCR43 cells, the expression of human CD4 is necessary for
the inhibitory e¡ect of gp120 on ADA binding, we show that
the expression of human CXCR4 clearly makes CD4 dispens-
able. This suggests that CXCR4 is su⁄cient to allow a func-
tional gp120^CD26 interaction. This is in our opinion the
reason why in human CXCR4 cells the blockade of CD4
has a low e¡ect on the inhibitory ability of gp120. The re-
quirement of CXCR4 for a functional gp120^CD26 interac-
tion could also explain the inhibitory e¡ect of gp120 on the
binding of ADA to the CD43/CXCR4 human B-cell line
SKW6.4 [15], and the lack of interaction between soluble
CD26 and recombinant soluble gp120 [10,28].
The third constant domain gp120 (C3 region) seems to be
responsible for ADA binding inhibition in murine cells (Fig.
2), as we reported for human cell lines [15]. Although the
interpretation of these data should be made with caution
due to the use of synthetic peptides, some speci¢city for this
e¡ect can be assumed, due to the fact that a complete collec-
tion of peptides covering the gp120 sequence was used [15].
The C3 region of gp120 seems to be hidden in both, the
recombinant oligomeric gp160 precursor protein and the
Fig. 3. The HIV-induced inhibition of 125I-labeled ADA binding to
human CD26 in murine cells requires gp120^CD4 interaction. A:
The e¡ect of 100 nM gp120 on the binding of 15 nM 125I-labeled
ADA to M9 cells (expressing human CD4) and M7 cells (lacking
human CD4) was studied as described in the legend of Fig. 2. Unla-
beled ADA was used as a control for speci¢c binding. B: The e¡ect
of anti-CD4 mAb CB-T4 on gp120- and HIV-1 particle-induced
125I-labeled ADA binding inhibition. The binding of 15 nM 125I-la-
beled ADA to W12 cells was studied in the presence or the absence
of 100 nM of gp120 or a concentrated preparation of HIV-1 Lai
particles. In both cases, cells were preincubated (15 min, 37‡C) with
or without the mAb CB-T4 (1 Wg/ml). Results of a typical experi-
ment are presented (mean þ S.E.M. from triplicate samples).
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monomeric gp120 [29]. Moreover, recently reported data on
the crystal structure of gp120 con¢rms that these sequences
are not exposed on the outer surface of the protein [30]. In the
context of gp120 interaction with the cell surface, if the C3
region is indeed responsible for ADA binding inhibition, the
interaction of gp120 with CD4 and/or CXCR4 would contrib-
ute to unmask this hidden region and allow inhibition of
ADA binding to CD26. Consistent with this hypothesis,
transfection of CXCR4, but not CCR5 increased the inhibi-
tory e¡ect of gp120 on the binding of ADA to CD26 (Fig. 4).
The modi¢cation on the distribution of cell surface mole-
cules after binding of gp120 to target cells has been reported
by several authors. Concerning CD4 and CXCR4, the binding
of gp120 induces an actin-dependent association of both re-
ceptors [26], that can be also observed in immunoprecipitation
assays [27]. In addition to CD4 and CXCR4, gp120 induces
cocapping of several cell surface molecules, CD26, CD45 and
CD3 among others [31]. CD45RO regulates the CD4-associ-
ated tyrosine kinase p56lck and associates the CD26 [32]. Fur-
thermore, the function and the anti-HIV activity of several
chemokines, such as the CXCR4 agonist SDF-1K, are modu-
lated by the peptidase activity of CD26 [14]. Given the func-
tional relationships between these proteins (CD26, CD4 and
CXCR4) on the cell surface, the presence of CD26 near these
CD4^CXCR4 complexes is an attractive possibility.
Cell-surface ADA has a protective e¡ect against locally
high concentrations of adenosine [33]. Moreover, it has been
reported that the blockade of ADA binding to CD26 by anti-
ADA antibodies impairs T-cell proliferation [8]. Thus, the
inhibition of ADA binding to CD26 exerted by gp120 might
alter early events of T-cell activation, in which the ADA^
CD26 interaction seems to be involved [34]. On the other
hand, the results described here may explain, at least in
part, the increased levels of serum ADA observed in HIV
infected individuals [16]. The e¡ect of gp120 on the ADA^
CD26 module is not limited to CD4 cells, but it also occurs
in CXCR4-expressing cells. In this regard, nocious e¡ects as-
sociated with a gp120^CXCR4 interaction have been reported
in neurons and CD8 T-cells [35,36]. The role of the ADA^
CD26 module in these e¡ects will merit attention.
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